In addition, MTHFD2 was validated to have the potential to accurately distinguish the molecular subtypes of BLCA in the GSE48075 cohort, in terms of the basal and luminal subtypes (Figures 6A, B). This evidence concerns the gene MTHFD2 and bladder transitional cell carcinoma.